STVN Insider William Federici Sells $26K of Stock

William Federici Sells Shares of Stevanato Group S.p.A.

William Federici recently executed a transaction involving Stevanato Group S.p.A. (NYSE:STVN), selling 1,493 shares on June 15, 2026. The stock was traded at a price of $17.09 per share, bringing the total value of the sale to $25,515.37. Insider transactions like this provide a look into how executive team members manage their personal holdings, though selling does not automatically signal a negative outlook for the business.

Insider Buying and Selling at Stevanato Group S.p.A.

This sale is part of a broader wave of insider moves at the company during June 2026. On June 9, Chief Business Strategy Officer Mauro Stocchi both acquired and disposed of 6,586 shares. Later in the week on June 12, a group of insiders including Sue-Jean Lin, Karen Flynn, and Elisabetta Magistretti each acquired 4,975 shares. Chief Financial Officer Dal Lago Marco also parted with 7,997 shares on June 12. These diverse transactions illustrate ongoing portfolio adjustments across the leadership team.

Stevanato Group Stock Performance

Shares of Stevanato Group traded hands recently around $18.39, sitting near the middle of its 52-week range that spans from a low of $12.89 to a high of $27.99. The company's shares are trading close to its 200-day moving average of $18.19, while lagging behind the 50-day moving average of $20.98. With a market capitalization of roughly $5.26 billion, the stock maintains a forward P/E ratio of 23.18.

Analysts Set New Price Targets

Financial firms continue to evaluate the medical technology provider's market position. On September 9, 2026, UBS maintained its neutral rating on the company while lowering its price target from $28.00 to $23.00. Across the broader analyst community tracked by market data, the stock holds a consensus buy recommendation backed by 13 opinions, with a mean price target resting at $24.47. <div></div>

What Stevanato Group Does

Stevanato Group S.p.A. designs, produces, and distributes specialized equipment and containment solutions for the biopharmaceutical and healthcare sectors globally. Its offerings include pre-fillable syringes, drug delivery systems, diagnostic components, and engineering machinery used in drug manufacturing. Headquartered in Piombino Dese, Italy, the company serves life sciences firms and drug makers with both product supplies and factory-floor support.

What's Ahead for Stevanato Group S.p.A.

Market observers will track further insider filings and prepare for the company's next scheduled financial results release on November 5, 2026. These scheduled disclosures offer more data on operational progress and revenue growth following recent quarters.